reased from 13% in 2010 to an estimated 18% in 2025. Company pipelines hav= also become more robust with a 54% increase since 2007 in the number of dr=gs gaining FDA approval. We think the sell-off which was due to the practices o= a few select companies was too broad and overdone. We would use this a